| 24.81 0.78 (3.25%) | 01-29 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 39.35  |
1-year : | 47.52 |
| Resists | First : | 33.69 |
Second : | 40.68 |
| Pivot price | 24.3 |
|||
| Supports | First : | 22.37 | Second : | 18.62 |
| MAs | MA(5) : | 24.85 |
MA(20) : | 25.15 |
| MA(100) : | 21.31 |
MA(250) : | 14.81 |
|
| MACD | MACD : | -1 |
Signal : | -1 |
| %K %D | K(14,3) : | 39 |
D(3) : | 37.7 |
| RSI | RSI(14): 45.1 |
|||
| 52-week | High : | 45 | Low : | 7.65 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ LYEL ] has closed below upper band by 33.5%. Bollinger Bands are 61.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 25.43 - 25.61 | 25.61 - 25.75 |
| Low: | 24.01 - 24.19 | 24.19 - 24.34 |
| Close: | 24.57 - 24.86 | 24.86 - 25.08 |
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Wed, 24 Dec 2025
Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data (NASDAQ:LYEL) - Seeking Alpha
Sun, 07 Dec 2025
Lyell Immunopharma (Nasdaq: LYEL) posts 76% complete responses with ronde-cel in LBCL - Stock Titan
Wed, 12 Nov 2025
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025 - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 1.218e+007 (%) |
| Held by Institutions | 27.6 (%) |
| Shares Short | 162 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.8438e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -248 % |
| Return on Assets (ttm) | 353.3 % |
| Return on Equity (ttm) | -24.2 % |
| Qtrly Rev. Growth | 41000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -22.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -165 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.21 |
| Dividend | 0 |
| Forward Dividend | 240730 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|